All In Biotech

Drug Trial Radar · NCT00121407

Visudyne® in Occult (VIO)

A Randomized, Placebo-Controlled, Double-Masked, Multicenter, Phase III Study of the Effect of Visudyne Therapy in Occult With No Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD): Visudyne in Occult (VIO)

Last checked: Nov 20, 2026Latest source record: Jul 21, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 364 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

364

Actual

Start

Mar 2002

Primary completion

Not stated

Study completion Aug 2005

Sponsor

Lead sponsor
QLT Inc.Industry
Sponsor type
Industry
First posted
Jul 21, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate that Visudyne therapy in patients who have occult with no classic subfoveal choroidal neovascularization (CNV) lesions will, with an acceptable safety profile, significantly reduce the risk of vision loss compared with placebo (sham treatment).

Conditions

  • Macular Degeneration

Interventions

  • Visudyne for injectionDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy variable is the patient responder rate. The patient responder rate has two definitions as described below:
  2. • The proportion of patients who lose less than 15 letters (<3 lines) of best-corrected visual acuity in the study eye from baseline
  3. • The proportion of patients who lose fewer than 30 letters (<6 lines) of best-corrected visual acuity in the study eye from baseline

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.